s6y ACURA PHARMACEUTICALS, INC 10-K
INCOME TAXES
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE 13 – INCOME TAXES
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017 and requiring adjustment to 2017 deferred taxes. The Company has calculated its best estimate of the impact of the Act in its year-end income tax provision in accordance with its understanding of the Act and guidance available as of the date of this filing and as a result had no adjustment to record as an additional income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted.
 
On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. In accordance with SAB 118, the Company has remeasured its deferred tax assets and liabilities and adjusted its deferred tax balances to reflect the lower enacted U.S. corporate tax rate resulted in an income tax expense of $26.6 million which is included as a discrete item in the 2017 income tax provision. Overall, there was no impact to the tax provision as a result of offsetting reduction of the valuation allowance. This deferred tax expense and valuation allowance were  provisional amounts and reasonable estimates at December 31, 2017.
 
Provision for Income Taxes
 
The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows (in thousands):
 
 
 
December 31,
 
 
 
2017
 
2016
 
Benefit at U.S. statutory 34% tax rate
 
$
(1,978)
 
$
(2,512)
 
State taxes (benefit), net of federal effect
 
 
(203)
 
 
(254)
 
State research and development tax credits
 
 
105
 
 
49
 
Federal research and development tax credits
 
 
(70)
 
 
-
 
Share-based compensation
 
 
116
 
 
159
 
Federal AMT tax credit
 
 
(135)
 
 
-
 
Other
 
 
(3)
 
 
2
 
Tax Cuts and Jobs Act of 2017
 
 
26,603
 
 
-
 
Change in valuation allowance
 
 
(24,570)
 
 
2,556
 
(Benefit) provision for income taxes
 
$
(135)
 
$
-
 
 
Deferred Tax Assets and Valuation Allowance
 
Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $167.7 million gross Federal NOLs at December 31, 2017 however we believe the ability for us to use these NOLs to offset any future taxable income is severely limited as prescribed under Internal Revenue Code (“IRC”) Section 382. We have estimated and recorded an amount for the likely limitation to our deferred tax asset, thereby reducing the aggregate estimated benefit of the Federal NOLs available to us of approximately $1.0 million. We believe the gross Federal NOL benefit we can utilize to offset taxable income is less than $150 thousand annually. Any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037. Future common stock transactions may cause another qualifying event under IRC 382 which may further limit our utilization of our NOLs.
The components of our deferred tax assets are as follows (in thousands):
 
 
 
December 31,
 
 
 
2017
 
2016
 
Deferred tax assets:
 
 
 
 
 
 
 
Estimated future value of NOLs
 
 
 
 
 
 
 
- Federal
 
$
1,028
 
$
47,192
 
- State
 
 
1,276
 
 
2,135
 
Research and development tax credits
 
 
 
 
 
 
 
- Federal
 
 
1,231
 
 
1,161
 
- State
 
 
-
 
 
159
 
Share-based compensation
 
 
66
 
 
57
 
Other, net
 
 
203
 
 
332
 
Total deferred taxes
 
 
3,804
 
 
51,036
 
Valuation allowance
 
 
(3,804)
 
 
(51,036)
 
Net deferred tax assets
 
$
-
 
$
-
 
 
Realization of deferred tax assets is dependent upon future earnings, if any, and the timing and amount of which may be uncertain. Valuation allowances are placed on deferred tax assets when uncertainty exists on their near term utilization. We make periodic reviews of our valuation allowances and fluctuations can occur. Those fluctuations may be reflected as income tax expenses or benefits in the period they occur. We continue to maintain full valuation allowance against all of our deferred tax assets at December 31, 2017 due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that amounts of our deferred tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and a benefit from income taxes in such period would be recognized.
Uncertainty in Income Taxes
 
We adopted FASB’s statement regarding accounting for uncertainty in income taxes which defined the threshold for recognizing the benefits of tax-return positions in the consolidated financial statements as "more-likely-than-not" to be sustained by the taxing authorities. Our adoption of the standard did not result in establishing a contingent tax liability reserve or a corresponding charge to retained earnings. At each of December 31, 2017 and 2016, we had no liability for income tax associated with uncertain tax positions. If in the future we establish a contingent tax liability reserve related to uncertain tax positions, our practice will be to recognize the interest in interest expense and the penalties in other non-operating expense.
 
The Company files federal and state income tax returns and in the normal course of business the Company is subject to examination by these taxing authorities. As of December 31, 2017, the Company’s tax years of 2014, 2015 and 2016 are subject to examination by the taxing authorities. With few exceptions, we believe the Company is no longer subject to U.S. Federal, State and local examinations by taxing authorities for years before 2014.